231 related articles for article (PubMed ID: 24166050)
1. V-ATPase inhibition by archazolid leads to lysosomal dysfunction resulting in impaired cathepsin B activation in vivo.
Kubisch R; Fröhlich T; Arnold GJ; Schreiner L; von Schwarzenberg K; Roidl A; Vollmar AM; Wagner E
Int J Cancer; 2014 May; 134(10):2478-88. PubMed ID: 24166050
[TBL] [Abstract][Full Text] [Related]
2. The vacuolar-type ATPase inhibitor archazolid increases tumor cell adhesion to endothelial cells by accumulating extracellular collagen.
Luong B; Schwenk R; Bräutigam J; Müller R; Menche D; Bischoff I; Fürst R
PLoS One; 2018; 13(9):e0203053. PubMed ID: 30204757
[TBL] [Abstract][Full Text] [Related]
3. The V-ATPase-inhibitor archazolid abrogates tumor metastasis via inhibition of endocytic activation of the Rho-GTPase Rac1.
Wiedmann RM; von Schwarzenberg K; Palamidessi A; Schreiner L; Kubisch R; Liebl J; Schempp C; Trauner D; Vereb G; Zahler S; Wagner E; Müller R; Scita G; Vollmar AM
Cancer Res; 2012 Nov; 72(22):5976-87. PubMed ID: 22986742
[TBL] [Abstract][Full Text] [Related]
4. Selective upregulation of TNFα expression in classically-activated human monocyte-derived macrophages (M1) through pharmacological interference with V-ATPase.
Thomas L; Rao Z; Gerstmeier J; Raasch M; Weinigel C; Rummler S; Menche D; Müller R; Pergola C; Mosig A; Werz O
Biochem Pharmacol; 2017 Apr; 130():71-82. PubMed ID: 28189727
[TBL] [Abstract][Full Text] [Related]
5. Anti-leukemic effects of the V-ATPase inhibitor Archazolid A.
Zhang S; Schneider LS; Vick B; Grunert M; Jeremias I; Menche D; Müller R; Vollmar AM; Liebl J
Oncotarget; 2015 Dec; 6(41):43508-28. PubMed ID: 26496038
[TBL] [Abstract][Full Text] [Related]
6. Differential regulation of AMP-activated protein kinase in healthy and cancer cells explains why V-ATPase inhibition selectively kills cancer cells.
Bartel K; Müller R; von Schwarzenberg K
J Biol Chem; 2019 Nov; 294(46):17239-17248. PubMed ID: 31604821
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of the V-ATPase by Archazolid A: A New Strategy to Inhibit EMT.
Merk H; Messer P; Ardelt MA; Lamb DC; Zahler S; Müller R; Vollmar AM; Pachmayr J
Mol Cancer Ther; 2017 Nov; 16(11):2329-2339. PubMed ID: 28775146
[TBL] [Abstract][Full Text] [Related]
8. Targeting V-ATPase in primary human monocytes by archazolid potently represses the classical secretion of cytokines due to accumulation at the endoplasmic reticulum.
Scherer O; Steinmetz H; Kaether C; Weinigel C; Barz D; Kleinert H; Menche D; Müller R; Pergola C; Werz O
Biochem Pharmacol; 2014 Oct; 91(4):490-500. PubMed ID: 25107704
[TBL] [Abstract][Full Text] [Related]
9. Resistance mechanisms of cancer cells to the novel vacuolar H(+)-ATPase inhibitor archazolid B.
Hamm R; Sugimoto Y; Steinmetz H; Efferth T
Invest New Drugs; 2014 Oct; 32(5):893-903. PubMed ID: 25065443
[TBL] [Abstract][Full Text] [Related]
10. Archazolid and apicularen: novel specific V-ATPase inhibitors.
Huss M; Sasse F; Kunze B; Jansen R; Steinmetz H; Ingenhorst G; Zeeck A; Wieczorek H
BMC Biochem; 2005 Aug; 6():13. PubMed ID: 16080788
[TBL] [Abstract][Full Text] [Related]
11. V-ATPase inhibition increases cancer cell stiffness and blocks membrane related Ras signaling - a new option for HCC therapy.
Bartel K; Winzi M; Ulrich M; Koeberle A; Menche D; Werz O; Müller R; Guck J; Vollmar AM; von Schwarzenberg K
Oncotarget; 2017 Feb; 8(6):9476-9487. PubMed ID: 28036299
[TBL] [Abstract][Full Text] [Related]
12. V-ATPase inhibition regulates anoikis resistance and metastasis of cancer cells.
Schempp CM; von Schwarzenberg K; Schreiner L; Kubisch R; Müller R; Wagner E; Vollmar AM
Mol Cancer Ther; 2014 Apr; 13(4):926-37. PubMed ID: 24482380
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and biological evaluation of a water-soluble derivative of the potent V-ATPase inhibitor archazolid.
Persch E; Basile T; Bockelmann S; Huss M; Wieczorek H; Carlomagno T; Menche D
Bioorg Med Chem Lett; 2012 Dec; 22(24):7735-8. PubMed ID: 23122818
[TBL] [Abstract][Full Text] [Related]
14. V-ATPase inhibition overcomes trastuzumab resistance in breast cancer.
von Schwarzenberg K; Lajtos T; Simon L; Müller R; Vereb G; Vollmar AM
Mol Oncol; 2014 Feb; 8(1):9-19. PubMed ID: 24055142
[TBL] [Abstract][Full Text] [Related]
15. Stereochemical determination of Archazolid A and B, highly potent vacuolar-type ATPase inhibitors from the Myxobacterium Archangium gephyra.
Hassfeld J; Farès C; Steinmetz H; Carlomagno T; Menche D
Org Lett; 2006 Oct; 8(21):4751-4. PubMed ID: 17020294
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, and biological evaluation of novel analogues of archazolid: a highly potent simplified V-ATPase inhibitor.
Menche D; Hassfeld J; Sasse F; Huss M; Wieczorek H
Bioorg Med Chem Lett; 2007 Mar; 17(6):1732-5. PubMed ID: 17239591
[TBL] [Abstract][Full Text] [Related]
17. Archazolid A-15-O-β-D-glucopyranoside and iso-archazolid B: potent V-ATPase inhibitory polyketides from the myxobacteria Cystobacter violaceus and Archangium gephyra.
Horstmann N; Essig S; Bockelmann S; Wieczorek H; Huss M; Sasse F; Menche D
J Nat Prod; 2011 May; 74(5):1100-5. PubMed ID: 21513292
[TBL] [Abstract][Full Text] [Related]
18. Vacuolar-ATPase Inhibition Blocks Iron Metabolism to Mediate Therapeutic Effects in Breast Cancer.
Schneider LS; von Schwarzenberg K; Lehr T; Ulrich M; Kubisch-Dohmen R; Liebl J; Trauner D; Menche D; Vollmar AM
Cancer Res; 2015 Jul; 75(14):2863-74. PubMed ID: 26018087
[TBL] [Abstract][Full Text] [Related]
19. Induction of cholesterol biosynthesis by archazolid B in T24 bladder cancer cells.
Hamm R; Chen YR; Seo EJ; Zeino M; Wu CF; Müller R; Yang NS; Efferth T
Biochem Pharmacol; 2014 Sep; 91(1):18-30. PubMed ID: 24976507
[TBL] [Abstract][Full Text] [Related]
20. Hyperacidification of trans-Golgi network and endo/lysosomes in melanocytes by glucosylceramide-dependent V-ATPase activity.
van der Poel S; Wolthoorn J; van den Heuvel D; Egmond M; Groux-Degroote S; Neumann S; Gerritsen H; van Meer G; Sprong H
Traffic; 2011 Nov; 12(11):1634-47. PubMed ID: 21810155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
